BG62229B2 - Моноклонални антитела срещу човешки туморнекротизиращ фактор и използването им - Google Patents
Моноклонални антитела срещу човешки туморнекротизиращ фактор и използването им Download PDFInfo
- Publication number
- BG62229B2 BG62229B2 BG098602A BG9860294A BG62229B2 BG 62229 B2 BG62229 B2 BG 62229B2 BG 098602 A BG098602 A BG 098602A BG 9860294 A BG9860294 A BG 9860294A BG 62229 B2 BG62229 B2 BG 62229B2
- Authority
- BG
- Bulgaria
- Prior art keywords
- tnf
- antibodies
- monoclonal antibodies
- cells
- tak
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 36
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 210000004754 hybrid cell Anatomy 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000012606 in vitro cell culture Methods 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 73
- 102000003390 tumor necrosis factor Human genes 0.000 description 73
- 239000000243 solution Substances 0.000 description 19
- 210000004408 hybridoma Anatomy 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 102000013415 peroxidase activity proteins Human genes 0.000 description 11
- 108040007629 peroxidase activity proteins Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 5
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000011330 nucleic acid test Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000009149 molecular binding Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101100022230 Caenorhabditis elegans mak-2 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000762448 Homo sapiens Cdc42 effector protein 1 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100236442 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mak-5 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000053274 human CDC42EP1 Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- UEOXFKPVURAKAA-RMYJOMHKSA-N streptide Chemical compound NCCC[C@@H]1[C@H](NC(=O)[C@H](C)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)C(C)C)CC2=CNC3=C1C=CC=C23 UEOXFKPVURAKAA-RMYJOMHKSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863631229 DE3631229A1 (de) | 1986-09-13 | 1986-09-13 | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG62229B2 true BG62229B2 (bg) | 1999-05-31 |
Family
ID=6309540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG098602A BG62229B2 (bg) | 1986-09-13 | 1994-02-28 | Моноклонални антитела срещу човешки туморнекротизиращ фактор и използването им |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5231024A (fr) |
| EP (1) | EP0260610B1 (fr) |
| JP (2) | JP2837160B2 (fr) |
| BG (1) | BG62229B2 (fr) |
| BR (1) | BR1100843A (fr) |
| CA (1) | CA1337717C (fr) |
| DE (2) | DE3631229A1 (fr) |
| DK (1) | DK473887A (fr) |
| ES (1) | ES2058083T3 (fr) |
| FI (1) | FI91421C (fr) |
| ZA (1) | ZA876807B (fr) |
Families Citing this family (174)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6419927B1 (en) | 1981-09-08 | 2002-07-16 | Anthony Cerami | Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages |
| US5700466A (en) * | 1981-09-08 | 1997-12-23 | The Rockefeller University | Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor |
| US6309640B1 (en) | 1981-09-08 | 2001-10-30 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| GB2233559B (en) * | 1988-03-11 | 1992-03-04 | Celltech Ltd | Antibodies for use in antilymphocyte antibody therapy |
| DE3823804A1 (de) * | 1988-07-14 | 1990-01-18 | Basf Ag | Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten |
| AU626572B2 (en) * | 1988-07-18 | 1992-08-06 | Chiron Corporation | Monoclonal antibodies reactive with cachectin |
| WO1990001950A1 (fr) * | 1988-08-19 | 1990-03-08 | Celltech Limited | Produits pharmaceutiques pour therapie anti-neoplastique |
| US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
| WO1991002078A1 (fr) * | 1989-08-07 | 1991-02-21 | Peptide Technology Ltd | Ligands de liaison du facteur de necrose de tumeurs |
| US20030225254A1 (en) * | 1989-08-07 | 2003-12-04 | Rathjen Deborah Ann | Tumour necrosis factor binding ligands |
| US5998378A (en) * | 1989-08-16 | 1999-12-07 | Chiron Corporation | Compositions for the inhibition of TNF hormone formation and uses thereof |
| US5843693A (en) * | 1989-08-16 | 1998-12-01 | Chiron Corporation | Assay method for screening for inhibitors of proTNF conversion |
| ATE189682T1 (de) * | 1989-08-16 | 2000-02-15 | Chiron Corp | Prohormonspaltungsplatzblockierungsantikörper |
| US6586222B1 (en) | 1989-08-16 | 2003-07-01 | Chiron Corporation | Recombinant PR-3 and compositions thereof |
| GB8921123D0 (en) * | 1989-09-19 | 1989-11-08 | Millar Ann B | Treatment of ards |
| US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| EP1905782A1 (fr) * | 1991-03-18 | 2008-04-02 | New York University | Anticorps monoclonaux et chimériques spécifiques pour le facteur onconécrosant humain |
| US20040120952A1 (en) * | 2000-08-07 | 2004-06-24 | Centocor, Inc | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| ATE172880T1 (de) * | 1992-08-28 | 1998-11-15 | Bayer Ag | Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden |
| US20050260201A1 (en) * | 1993-01-29 | 2005-11-24 | Centocor, Inc. | Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5626843A (en) * | 1993-02-26 | 1997-05-06 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor |
| DE4409513C1 (de) * | 1994-02-07 | 1995-10-19 | Knoll Ag | Verwendung von anti-TNF-Antikörpern als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel |
| NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
| EP0749494A1 (fr) | 1994-03-07 | 1996-12-27 | Chiron Corporation | Compositions pour l'inhibition de la formation des facteurs de necrose tumorale (tnf) et leur utilisation |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| NZ512006A (en) | 1996-02-09 | 2005-05-27 | Abbott Biotech Ltd | Medical treatment with human TNF-alpha antibodies |
| US7608262B2 (en) * | 1996-02-16 | 2009-10-27 | The Kennedy Institute Of Rheumatology | Methods of preventing or treating thrombosis with tumor necrosis factor antagonists |
| PT1500329E (pt) * | 1996-12-03 | 2012-06-18 | Amgen Fremont Inc | Anticorpos humanos que se ligam especificamente ao tnf alfa humano |
| US20020031513A1 (en) * | 1997-11-24 | 2002-03-14 | Shamir Leibovitz | Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals |
| JP2002538170A (ja) * | 1999-03-02 | 2002-11-12 | セントコール， インコーポレイテッド | 喘息の治療における抗−ＴＮＦα抗体 |
| KR100672892B1 (ko) * | 1999-03-18 | 2007-01-23 | 셀진 코오퍼레이션 | 치환된 1-옥소- 및 1,3-디옥소이소인돌린스 및 염증성사이토킨 수치를 감소시키기 위한 약학적 조성물로서의이들의 사용 |
| EP1239877B1 (fr) * | 1999-10-06 | 2008-01-09 | Abbott GmbH & Co. KG | Composition comprenant un inhibiteur du tnf-alpha et d'un antagoniste du recepteur alphavbeta3 d'integrine |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| US20090081234A1 (en) * | 2000-08-07 | 2009-03-26 | George Heavner | Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions |
| US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
| US20060018907A1 (en) * | 2000-08-07 | 2006-01-26 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| US20110195063A1 (en) * | 2000-08-07 | 2011-08-11 | Centocor, Inc. | Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor |
| AU2002306651B2 (en) * | 2001-03-02 | 2007-12-13 | Medimmune, Llc | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists |
| CA2868614A1 (fr) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methodes pour administrer des anticorps anti-tnf.alpha. |
| TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| WO2003086458A1 (fr) * | 2002-04-12 | 2003-10-23 | Medimmune, Inc. | Anticorps anti-interleukine-9 recombinants |
| US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| EP1545608A4 (fr) | 2002-06-28 | 2006-09-13 | Centocor Inc | Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations |
| CN102755646A (zh) | 2002-07-19 | 2012-10-31 | 艾博特生物技术有限公司 | TNF α相关疾病的治疗 |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| AU2003298816C1 (en) | 2002-12-02 | 2010-12-16 | Amgen Fremont, Inc. | Antibodies directed to Tumor Necrosis Factor and uses thereof |
| US7101978B2 (en) * | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| ES2391087T3 (es) | 2003-04-11 | 2012-11-21 | Medimmune, Llc | Anticuerpos de IL-9 recombinantes y usos de los mismos |
| US20040229878A1 (en) * | 2003-05-13 | 2004-11-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of P38 kinase |
| US8273347B2 (en) * | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
| US7344716B2 (en) | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
| US7429378B2 (en) * | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
| MXPA05012275A (es) | 2003-05-13 | 2006-02-10 | Depuy Spine Inc | Un metodo para tratar enfermedad degenerativa del disco. |
| US7553827B2 (en) * | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
| US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
| UA89481C2 (uk) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
| US8895540B2 (en) * | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| US7435799B2 (en) * | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
| EP1750754A4 (fr) * | 2004-03-31 | 2010-09-22 | Centocor Ortho Biotech Inc | Corps mimetiques glp-1 humains, compositions, procedes et utilisations |
| TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| WO2006041970A2 (fr) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Infection a virus respiratoire syncytial (rsv) |
| JP2008518023A (ja) | 2004-10-27 | 2008-05-29 | メディミューン，インコーポレーテッド | 同族抗原に対する親和性を改変することによる抗体特異性の調節 |
| PA8672101A1 (es) | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
| EP1885397A4 (fr) * | 2005-05-16 | 2010-01-20 | Abbott Biotech Ltd | UTILISATION DE L'INHIBITEUR DU TNF-a POUR TRAITER LA POLYARTHRITE ÉROSIVE |
| CN101252951B (zh) | 2005-06-30 | 2011-12-21 | 森托科尔公司 | 抗il-23抗体、组合物、方法和用途 |
| AU2006274698B2 (en) * | 2005-08-02 | 2011-06-09 | Xbiotech, Inc. | Diagnosis, treatment, and prevention of vascular disorders using IL-1a autoantibodies |
| US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| EP1948206B1 (fr) | 2005-08-30 | 2017-03-01 | Intrexon Actobiotics NV | Bacterie produisant de l'anti-tnf-alfa pour le traitement des maladies intestinales inflammatoires |
| CA2626804A1 (fr) | 2005-11-01 | 2007-08-09 | Abbott Biotechnology Ltd. | Methodes et compositions de diagnostic de la spondylarthrite ankylosante a l'aide de biomarqueurs |
| LT2548577T (lt) | 2005-12-29 | 2017-04-10 | Janssen Biotech, Inc. | Žmogaus anti-il-23 antikūnai, kompozicijos, būdai ir panaudojimai |
| NZ571479A (en) | 2006-04-05 | 2012-10-26 | Abbott Biotech Ltd | Antibody purification |
| US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| WO2007120656A2 (fr) * | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde |
| WO2008063213A2 (fr) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications |
| EP2703010A3 (fr) | 2006-04-10 | 2014-08-06 | AbbVie Biotechnology Ltd | Utilisations et compositions pour le traitement de l'arthrite rhumatoïde |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
| CN107158376A (zh) * | 2006-05-22 | 2017-09-15 | 埃克斯生物科技公司 | 使用抗IL‑1α抗体治疗癌症 |
| CN103316403B (zh) | 2006-06-30 | 2017-05-24 | 艾伯维生物技术有限公司 | 自动注射装置 |
| EP2851064A3 (fr) | 2006-07-11 | 2015-08-05 | Roy C. Levitt | Prévention de la rhinosinusite et thérapie avec des inhibiteurs de cytokine proinflammatoires |
| US20080014285A1 (en) * | 2006-07-13 | 2008-01-17 | Di Mauro Thomas M | Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound |
| DK2068889T3 (da) | 2006-08-10 | 2020-02-03 | Roy C Levitt | Anakinra til anvendelse i behandling af bronchiolitis obliterans syndrom |
| CN104072612A (zh) * | 2006-10-27 | 2014-10-01 | 艾伯维生物技术有限公司 | 结晶型抗-hTNFα抗体 |
| RU2476442C2 (ru) | 2007-03-29 | 2013-02-27 | Эббот Лэборетриз | Кристаллические антитела против il-12 человека |
| BRPI0811466A2 (pt) | 2007-05-07 | 2014-10-14 | Medimmune Llc | Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica. |
| WO2008154543A2 (fr) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Procédés de traitement de l'arthrite idiopathique juvénile |
| WO2009020654A1 (fr) * | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions et procédés permettant la cristallisation d'anticorps |
| US20090038182A1 (en) * | 2007-08-09 | 2009-02-12 | Lans Maris J | Footwear with built-in scale |
| US20090162351A1 (en) * | 2007-12-21 | 2009-06-25 | Depuy Spine, Inc. | Transdiscal administration of inhibitors of p38 MAP kinase |
| US8986696B2 (en) * | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
| CA2710779C (fr) | 2007-12-31 | 2017-06-20 | Bayer Schering Pharma Aktiengesellschaft | Anticorps du tnf.alpha. |
| NZ601913A (en) * | 2008-01-15 | 2014-02-28 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
| ES2576681T3 (es) * | 2008-05-30 | 2016-07-08 | Xbiotech, Inc | Anticuerpos IL-1 alfa |
| CN102209557A (zh) * | 2008-09-12 | 2011-10-05 | 埃克斯生物科技公司 | 靶向病原性单核细胞 |
| US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
| BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
| BRPI1012162A2 (pt) | 2009-04-29 | 2016-01-12 | Abbott Biotech Ltd | dispositivo de injeção automática |
| JP5697677B2 (ja) | 2009-10-26 | 2015-04-08 | ネステク ソシエテ アノニム | 抗ｔｎｆ薬及び自己抗体の検出用アッセイ |
| WO2011075524A1 (fr) | 2009-12-15 | 2011-06-23 | Abbott Biotechnology Ltd | Poussoir de déclenchement amélioré pour dispositif d'injection automatique |
| EP2525822B1 (fr) | 2010-01-20 | 2017-05-10 | Merck Sharp & Dohme Corp. | Immunorégulation par des anticorps anti-ilt5 et fragments d'anticorps se liant à ilt5 |
| JP2013517330A (ja) | 2010-01-20 | 2013-05-16 | トーラックス インコーポレイテッド | 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片 |
| ES2703774T3 (es) | 2010-06-18 | 2019-03-12 | Xbiotech Inc | Tratamiento para la artritis |
| ES2856723T3 (es) | 2010-08-23 | 2021-09-28 | Janssen Biotech Inc | Tratamiento para enfermedades neoplásicas |
| JP5960707B2 (ja) | 2010-10-18 | 2016-08-02 | ネステク ソシエテ アノニム | 抗薬物抗体アイソタイプを決定するための方法 |
| AR084210A1 (es) * | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| EP2749305B1 (fr) | 2011-01-24 | 2017-11-01 | AbbVie Biotechnology Ltd | Dispositifs d'injection automatique présentant des surfaces de préhension surmoulées |
| PE20141543A1 (es) | 2011-01-24 | 2014-11-23 | Abbvie Biotechnology Ltd | Extraccion de protectores de aguja desde jeringas y dispositivos de inyeccion automatica |
| DK2676137T3 (en) | 2011-02-17 | 2015-01-19 | Nestec Sa | TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS |
| CN102675460B (zh) | 2011-02-28 | 2015-08-19 | 珠海市丽珠单抗生物技术有限公司 | 抗肿瘤坏死因子α的人源化抗体 |
| US8658171B2 (en) | 2011-02-28 | 2014-02-25 | Livzon Mabpharm Inc. | Humanized anti-TNFα antibodies |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| EP2702077A2 (fr) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante |
| EP2729807B1 (fr) | 2011-07-06 | 2016-08-17 | Nestec S.A. | Essais pour la détection d'auto-anticorps neutralisants vis-à-vis d'une thérapie biologique par tnf alpha |
| RU2622021C2 (ru) | 2011-09-23 | 2017-06-08 | ИксБиотеч, Инк. | Лечение кахексии |
| MX2014004980A (es) * | 2011-10-24 | 2014-09-11 | Abbvie Inc | Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17. |
| EP2771362A1 (fr) | 2011-10-24 | 2014-09-03 | AbbVie Inc. | Agents de liaison immunologique dirigés contre le tnf |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158273A1 (fr) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Procédés de modulation de la distribution de variant de lysine c-terminal |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| CA2883272A1 (fr) | 2012-09-02 | 2014-03-06 | Abbvie Inc. | Procedes de controle de l'heterogeneite des proteines |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| WO2014159579A1 (fr) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| CA2926301A1 (fr) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Compositions d'especes faiblement acides et leurs procedes de production et d'utilisation |
| WO2014151901A1 (fr) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Amélioration de la performance de la culture de cellules de mammifère au moyen d'une supplémentation de milieux d'alimentation en tensioactifs |
| WO2014151878A2 (fr) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides |
| SG11201507365VA (en) | 2013-03-14 | 2015-10-29 | Abbvie Inc | Low acidic species compositions and methods for producing the same using displacement chromatography |
| ES2690047T3 (es) | 2013-03-15 | 2018-11-19 | Janssen Biotech, Inc. | Procedimientos de fabricación para controlar la lisina C-terminal, la galactosa y el contenido de ácido siálico en proteínas recombinantes |
| EP3052640A2 (fr) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2015073884A2 (fr) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Compositions de protéines de liaison génétiquement glycomodifiées |
| US20170183376A1 (en) | 2014-06-24 | 2017-06-29 | Insight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
| US20170226552A1 (en) | 2014-07-03 | 2017-08-10 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt |
| WO2016007764A1 (fr) | 2014-07-09 | 2016-01-14 | Abbvie Inc. | Procédés pour moduler le profil de glycosylation de protéines recombinantes au moyen de sucres non utilisés couramment |
| ES2735085T3 (es) | 2014-12-05 | 2019-12-16 | Nestle Sa | Ensayos de cambio de movilidad homogéneos indirectos para la detección de agentes biológicos en muestras de pacientes |
| EP3078675A1 (fr) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Régime de dosage à induction pour le traitement des maladies liées au tnf alpha |
| US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
| JOP20190162A1 (ar) | 2016-12-30 | 2019-06-27 | Biocad Joint Stock Co | تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني |
| AU2017396503A1 (en) | 2017-01-30 | 2019-07-11 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Psoriatic arthritis |
| WO2018147915A1 (fr) | 2017-02-07 | 2018-08-16 | Janssen Biotech, Inc. | Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active |
| JP7145162B2 (ja) | 2017-02-16 | 2022-09-30 | ヤンセン バイオテク，インコーポレイテッド | 化膿性汗腺炎の処置 |
| BR112021013903A2 (pt) | 2019-01-15 | 2021-09-21 | Janssen Biotech, Inc. | Composições e métodos de anticorpos anti-tnf para o tratamento da artrite idiopática juvenil |
| CA3127748A1 (fr) | 2019-01-23 | 2020-07-30 | Janssen Biotech, Inc. | Compositions d'anticorps anti-tnf destinees a etre utilisees dans des methodes de traitement d'arthrite psoriasique |
| EA202192508A1 (ru) | 2019-03-14 | 2022-03-29 | Янссен Байотек, Инк. | Способы получения композиций антитела к фно |
| EP3938390A1 (fr) | 2019-03-14 | 2022-01-19 | Janssen Biotech, Inc. | Procédés de fabrication pour la production de compositions d'anticorps anti-tnf |
| EP3938391A1 (fr) | 2019-03-14 | 2022-01-19 | Janssen Biotech, Inc. | Procédés de production de compositions d'anticorps anti-tnf |
| KR20220012883A (ko) | 2019-05-23 | 2022-02-04 | 얀센 바이오테크 인코포레이티드 | Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법 |
| CN114173873A (zh) | 2019-06-03 | 2022-03-11 | 詹森生物科技公司 | 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法 |
| EP3976648A1 (fr) | 2019-06-03 | 2022-04-06 | Janssen Biotech, Inc. | Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique |
| JP2022540764A (ja) | 2019-06-25 | 2022-09-20 | プロサイセデクス インコーポレイティド | 抗ＴＮＦα生物製剤および抗薬剤抗体の検出 |
| WO2021028752A1 (fr) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anticorps anti-tfn pour le traitement du diabète de type i |
| JP2023551542A (ja) | 2020-11-30 | 2023-12-08 | エニグマ バイオインテリジェンス，インコーポレイテッド | アルツハイマー病の非侵襲的評価 |
| JP2023554200A (ja) | 2020-12-09 | 2023-12-26 | エイチケー イノ．エヌ コーポレーション | 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途 |
| JP2024526315A (ja) | 2021-07-09 | 2024-07-17 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｔｎｆ抗体組成物を製造するための製造方法 |
| JP2024527586A (ja) | 2021-07-09 | 2024-07-25 | ヤンセン バイオテツク，インコーポレーテツド | 抗－ｔｎｆ抗体組成物を産生するための製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0780914B2 (ja) * | 1984-04-02 | 1995-08-30 | 旭化成工業株式会社 | ヒト腫瘍壊死因子に対する抗体 |
| JPS60209528A (ja) * | 1984-04-03 | 1985-10-22 | Asahi Chem Ind Co Ltd | ヒト腫瘍壊死因子の精製方法 |
| JPS6163698A (ja) * | 1984-09-05 | 1986-04-01 | Asahi Chem Ind Co Ltd | 生理活性物質に対するモノクロ−ナル抗体とそれを用いる生理活性物質の精製方法 |
| IL73883A (en) * | 1984-12-20 | 1990-12-23 | Yeda Res & Dev | Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha |
| US4870163A (en) * | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
-
1986
- 1986-09-13 DE DE19863631229 patent/DE3631229A1/de not_active Withdrawn
-
1987
- 1987-09-08 US US07/094,289 patent/US5231024A/en not_active Expired - Fee Related
- 1987-09-11 EP EP87113278A patent/EP0260610B1/fr not_active Expired - Lifetime
- 1987-09-11 CA CA000546724A patent/CA1337717C/fr not_active Expired - Fee Related
- 1987-09-11 DE DE87113278T patent/DE3787241D1/de not_active Expired - Fee Related
- 1987-09-11 ZA ZA876807A patent/ZA876807B/xx unknown
- 1987-09-11 ES ES87113278T patent/ES2058083T3/es not_active Expired - Lifetime
- 1987-09-11 JP JP62226755A patent/JP2837160B2/ja not_active Expired - Fee Related
- 1987-09-11 FI FI873948A patent/FI91421C/fi not_active IP Right Cessation
- 1987-09-11 DK DK473887A patent/DK473887A/da not_active Application Discontinuation
-
1994
- 1994-02-28 BG BG098602A patent/BG62229B2/bg unknown
-
1996
- 1996-12-27 JP JP8349507A patent/JP2758394B2/ja not_active Expired - Fee Related
-
1997
- 1997-05-12 BR BR1100843-1A patent/BR1100843A/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2058083T3 (es) | 1994-11-01 |
| DK473887A (da) | 1988-03-11 |
| DE3631229A1 (de) | 1988-03-24 |
| EP0260610A2 (fr) | 1988-03-23 |
| FI873948A0 (fi) | 1987-09-11 |
| JPS63157977A (ja) | 1988-06-30 |
| EP0260610A3 (en) | 1989-01-11 |
| JP2837160B2 (ja) | 1998-12-14 |
| FI873948A (fi) | 1988-03-14 |
| FI91421C (fi) | 1994-06-27 |
| ZA876807B (en) | 1989-05-30 |
| JP2758394B2 (ja) | 1998-05-28 |
| US5231024A (en) | 1993-07-27 |
| JPH09294584A (ja) | 1997-11-18 |
| DK473887D0 (da) | 1987-09-11 |
| DE3787241D1 (de) | 1993-10-07 |
| BR1100843A (pt) | 2000-04-18 |
| CA1337717C (fr) | 1995-12-12 |
| EP0260610B1 (fr) | 1993-09-01 |
| FI91421B (fi) | 1994-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG62229B2 (bg) | Моноклонални антитела срещу човешки туморнекротизиращ фактор и използването им | |
| US5047507A (en) | Monoclonal antibodies with specificity affinity for human carcinoembryonic antigen | |
| JPS62187417A (ja) | 緑膿菌血清型に対する交さ反応性かつ交さ防御性単クロ−ン性抗体 | |
| EP0476226B1 (fr) | Anticorps monoclonaux contre IgE humaine | |
| Ball et al. | Isolation and characterization of monoclonal antibodies to (Na++ K+)-ATPase | |
| JPH0672158B2 (ja) | 精製されたヒトマクロファージ遊走阻止因子 | |
| EP0487610B1 (fr) | Anticorps prohormone pour blocage du site de clivage | |
| US5053492A (en) | Immunopurification using monoclonal antibodies to Mojave toxin | |
| Bankert et al. | Screening and replica plating of anti-hapten hybridomas with a transfer template hemolytic spot assay | |
| US4803167A (en) | Monoclonal antidigoxtin antibodies | |
| JP3745411B2 (ja) | モノクローナル抗体 | |
| Marhaug et al. | Monoclonal hybridoma antibodies to human amyloid related protein SAA. | |
| RU2105062C1 (ru) | Конъюгат на основе анти-jgm-антитела (варианты) и способ снижения секреции jgm антитела лимфоцитами (варианты) | |
| RU2049818C1 (ru) | Штамм гибридных культивируемых клеток мыши mus musculus l., испольуемый для получения моноклональных антител к дигоксину | |
| RU2117042C1 (ru) | Штамм культивируемых гибридных клеток животного mus musculus - продуцент моноклонального антитела к термостабильному компоненту капсулоподобной субстанции возбудителя мелиоидоза | |
| US5352584A (en) | Monoclonal antibodies which bind (E)-5- (2-bromovinyl)-arabinofuranosyluracil and diagnostic methods based thereon | |
| RU2003682C1 (ru) | Штамм гибридных культивируемых клеток животных MUS MUSCULUS L. - продуцент моноклональных антител к @ -легким цеп м иммуноглобулинов человека | |
| JPH0690784A (ja) | モノクローナル抗体及びその利用 | |
| CA2014006A1 (fr) | Anticorps monoclonaux contre des composes tetracycliques, procede de production et application | |
| JPS61249999A (ja) | モノクロ−ナル抗体 | |
| Bedi et al. | Monoclonal Antibodies to Rat Plasma Kininogen | |
| JPH04248991A (ja) | ヒトガラクト−ス転移酵素に特異的なモノクローナル抗体及び該抗体を産生するハイブリドーマ | |
| CA2056118A1 (fr) | Anticorps monoclonaux qui lient la proteine fixatrice du mannose | |
| JPH0488997A (ja) | モノクローナル抗体、これを産生するハイブリドーマ細胞株およびこれを用いた標識法 | |
| JPH02177897A (ja) | モノクローナル抗体及び該抗体を使用する生物質の免疫測定法 |